Several years ago, my linguistic research team and I began developing a computational tool we call "Read-y Grammarian." Our ...

Ready.COM to Arm based modules – application-ready hardware and software building blocks SAN DIEGO, CA, UNITED STATES, March 11, 2026 /EINPresswire.com/ — Nuremberg, Germany/San Diego, CA, March 10, ...

Over the past decades, computer scientists have developed numerous artificial intelligence (AI) systems that can process human speech in different languages. The extent to which these models replicate ...

Perplexity wants to be more than just an answer engine. On Wednesday, it launched Personal Computer, a new AI agent tool that can turn a spare Mac into a locally run AI system, pitching it as “a ...

In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, ...

AI chatbots are standardizing how people speak, write, and think. If this homogenization continues unchecked, it risks reducing humanity's collective wisdom and ability to adapt, computer scientists ...

A series of recent experiments have demonstrated that artificial intelligence can now reconstruct the meaning of a person’s inner thoughts directly from brain signals, in some cases without any ...

The crackle of electricity inside your brain has long been too complex to decode. Artificial intelligence is changing that.

"It's like controlling a character in a video game," one patient said. "You don't consciously think about moving a joystick in a certain direction. You simply think about where you want to go, and the ...

Anthropic on Wednesday announced that it has acquired Vercept, an AI startup with deep roots to some of the biggest names in Seattle’s tech scene. The acquisition marks the latest after Anthropic ...

International Business Machines stock is getting slammed Monday, becoming the latest perceived victim of rapidly developing AI technology, after Anthropic said its Claude Code tool could be used to ...

China’s brain-computer interface industry is rapidly scaling from research to commercialization, driven by strong policy support, expanding clinical trials, and growing investor interest.